News

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels.

Press Releases

BIO Statement on Most Favored Nation

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies:"For too many years, Americans have subsidized the research…

Learn more

BIO Statement on Industry Tariffs

WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on the potential for 100% tariffs on branded or patented medicines in the US:“We share the Administration’s…

Learn more

BIO Extends Agreement with Avantor for Five…

Collaboration maximizes BIO members’ access to Avantor’s market-leading portfolio of products, materials, and services to accelerate scientific innovation. WASHINGTON, D.C., September 17, 2025 - The Biotechnology Innovation Organization (BIO)…

Learn more

Letters, Testimony, & Comments

Browse All

BIO Statement on Vaccines and Autism

Phyllis Arthur, EVP, Health Policy and Programs, “Vaccines are one of the most important and effective innovations for the defense of public health. They have saved millions of lives and drastically reduced or eliminated deadly and debilitating…

Learn more

BIO's Comments to CDC’s Advisory Committee on…

Re: Docket No. CDC-2025-0454; Advisory Committee on Immunization Practices (ACIP)The Biotechnology Innovation Organization (BIO) is appreciative of the opportunity to provide comments to the Advisory Committee on Immunization Practices (ACIP) in…

Learn more

CSBA Letter to Congressional Leaders Supporting…

Dear Majority Leader Thune, Minority Leader Schumer, Speaker Johnson, and Minority Leader Jeffries:The Council of State Bioscience Associations (CSBA) is a coalition of independent state and territory based non-profit trade associations, each of…

Learn more

Amicus Briefs

Browse All

BIO Files Amicus Brief in Case Addressing Anti…

BIO filed an amicus brief in the U.S. Court of Appeals for the District of Columbia Circuit, seeking the reversal of a lower court decision that found plaintiff Vertex Pharmaceuticals’ patient assistance program in violation of the Anti-Kickback…

Learn more

BIO Files Amicus Brief in Delaware Supreme Court…

BIO filed an amicus brief in the Supreme Court of the State of Delaware, urging the Court to exclude Plaintiffs’ expert opinion, thereby ensuring that Delaware’s standard for the admission of such evidence remains consistent with the federal …

Learn more

BIO Files Amicus Briefs Supporting the Lawfulness…

On February 10, 2025, BIO filed an amicus brief in the U.S. District Court for the District of Columbia, supporting the lawfulness of plaintiff Eli Lilly's proposed 340B rebate model. The 340B Drug Pricing Program ("340B"), through which Medicaid…

Learn more